Related Experiment Video
Updated: May 22, 2026

Deep Dermal Injection As a Model of Candida albicans Skin Infection for Histological Analyses
Published on: June 13, 2018
[Daptomycin in complicated skin and soft tissue infections]
José Barberán1, M Carmen Fariñas
1Unidad de Enfermedades Infecciosas, Hospital Central de Defensa Gómez Ulla, Madrid, España. josebarberan@teleline.es
Methicillin-resistant Staphylococcus aureus (MRSA) is a growing threat in skin infections. Daptomycin offers a promising treatment option for these difficult-to-treat infections.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Context:
- Staphylococcus aureus is a leading cause of skin and soft tissue infections (SSTIs).
- Increasing rates of methicillin resistance and reduced vancomycin susceptibility in S. aureus pose treatment challenges.
Purpose:
- To evaluate daptomycin as a potential therapeutic agent for SSTIs.
- To highlight daptomycin's suitability for infections caused by resistant S. aureus strains.
Summary:
- Daptomycin exhibits favorable microbiological activity, pharmacokinetics, and safety profiles.
- Clinical experience supports the use of daptomycin in treating SSTIs.
- Daptomycin is particularly effective against methicillin-resistant S. aureus (MRSA).
Impact:
- Provides a viable therapeutic option for challenging SSTIs.
- Addresses the clinical need for effective treatments against antibiotic-resistant bacteria.
- Contributes to the management of MRSA infections.
Related Concept Videos
Staphylococcal Skin Infections
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Clinical Significance of Antibiotic Resistance
Estimation of k and VD of Aminoglycosides
Acute Pyelonephritis II: Diagnostic Studies and Management
Diphtheria